... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wol... more ... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wolfgang Loibl 6, Ulrike Pröbstl 7 ... Transdisciplinary research uses an interdisciplinary approach and cooperation with part-ners from outside the scientific community to tackle problems ...
... Vienna, Austria; 3 Institute of Forest Growth and Yield, University of Agriculture, Vienna, A... more ... Vienna, Austria; 3 Institute of Forest Growth and Yield, University of Agriculture, Vienna, Austria (∗ author for correspondence, e-mail: Robert.Jandl@fbva ... 10 7.5YR2/1 Sandy loam Slightly stony, high content in organic mat-ter, poorly expressed mottles, weak suban-gular blocks ...
Background Few data exist reporting the incidence of World Health Organization (WHO)-defined acut... more Background Few data exist reporting the incidence of World Health Organization (WHO)-defined acute myeloid leukemia (AML) subgroups in adults in Europe,1 but the incidence of AML with myelodysplastic-related features (MRF) may be higher than initially reported.2–4 Whether the presence of multilineage dysplasia has an independent prognostic impact in AML is still controversial.5,6 However, AML patients with preceding myelodysplastic syndrome (MDS)/myeloproliferative neoplasm and/or MDS-related cytogenetics (Medical Research Council [MRC]) have been shown to have poorer survival than AML-not otherwise specified (NOS).7 Previous studies of AML patients treated with azacitidine (AZA) included AML-MRF patients, but did not report on outcomes separately.3,4, 8–12 Methods Due to the lack of data assessing the prognostic impact of AML-MRF in elderly AML patients treated with AZA, we analyzed patients with AML-MRF from the Austrian AZA Registry, which was initiated to gain a comprehensive vi...
Background The prognosis of patients with relapsed/refractory acute myeloid leukemia (AML) follow... more Background The prognosis of patients with relapsed/refractory acute myeloid leukemia (AML) following intensive chemotherapy (IC) is poor; furthermore, treatment options for these patients are limited. Few studies have assessed outcomes of azacitidine (AZA) in a relapsed/refractory setting.1–3 Response rates and survival in these studies have been variable. Methods The Austrian AZA Registry was initiated to gain a comprehensive view of the use, safety and efficacy of AZA in a broad range of ‘real-life’ AML patients. The sole inclusion criteria were the diagnosis of AML according to World Health Organization (WHO) criteria and treatment with ≥1 dose of AZA. Here, we assess clinical outcomes in patients with newly diagnosed AML (AZA 1st line) vs patients with relapsed/refractory AML following IC and/or low-dose chemotherapy/other disease-modifying therapy (AZA ≥2nd line). Results Baseline characteristics were generally comparable between patients treated with AZA 1st line (n=170) and A...
Background Approximately 10% of cases of acute myeloid leukemia (AML) arise following exposure to... more Background Approximately 10% of cases of acute myeloid leukemia (AML) arise following exposure to chemotherapy (treatment-related AML [tAML]). Compared to de novo AML patients, tAML patients have a poor prognosis, not least due to a higher proportion having adverse cytogenetics. Treatment options for tAML patients are limited and outcomes remain dismal. Median overall survival (OS) of 6.9 mo as of initial presentation, with 25% deaths within one month of diagnosis, was reported for a large cohort of tAML patients, with individualized treatments ranging from supportive care, to intensive chemotherapy (IC) and bone marrow (BM) transplantation.1 Few studies have assessed azacitidine (AZA) in patients with tAML, and those that have, did not report separate outcomes for this subgroup.2–4 Methods Here, we compare a subgroup of tAML patients (n=27) with patients with other World Health Organization (WHO)-AML subgroups (n=319) from the Austrian AZA Registry. The aim of the registry was to g...
Crown-condition assessment, hypothesized to estimate needle losses following damage from several ... more Crown-condition assessment, hypothesized to estimate needle losses following damage from several sources, one of which might be air pollution, suffers from the subjective notion of a standard "healthy" tree. On the other hand, the foliage biomass - sapwood area ratios are reported to depend on a number of factors, e.g., site quality, stand density, crown class, and tree ring width conductivity. The authors hypothesize that early sapwood area might help to even better estimate needle biomass of Norway spruce (Picea abies (L.) Karst.) and to help standardize crown-condition assessment. Thirty-six Norway spruce trees at two Austrian sites, from three age-classes, three crown classes, and two crown-condition classes were felled. Needle mass, cross-sectional area, sapwood area, and early sapwood area (i.e., sapwood area excluding latewood) were measured. The results of this study indicate that indeed early sapwood area is a good estimator of foliage, independent of site, age, crown class, and crown condition. The ratio between early sapwood area and cross-sectional area could be a good estimator for crown condition and thus help to standardize crown-condition assessments by different surveyors.
ABSTRACT Original inClimate Change and Impacts on Water SupplyAppendix IForests, Water Protection... more ABSTRACT Original inClimate Change and Impacts on Water SupplyAppendix IForests, Water Protection and Climate ChangeReports of the BOKU -- Forest Group to WP 5
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone mar... more Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). We herein update this report with a population almost twice as large (n = 302). This cohort included 172 patients with >30 % BM blasts; 93 % would have been excluded from the pivotal AZA-001 trial (which led to European Medicines Agency (EMA) approval of azacitidine for high-risk myelodysplastic syndromes (MDS) and AML with 20-30 % BM blasts). Despite this much more unfavorable profile, results are encouraging: overall response rate was 48 % in the total cohort and 72 % in patients evaluable according to MDS-IWG-2006 response criteria, respectively. Median OS was 9.6 (95 % CI 8.53-10.7) months. A clinically relevant OS ben...
Background Several studies, including retrospective analyses of patient registries1,2 and a suban... more Background Several studies, including retrospective analyses of patient registries1,2 and a subanalysis of the phase III MDS-AZA-001 trial3 suggest that poor-risk cytogenetics negatively impact overall survival (OS) in patients with myelodysplastic syndrome (MDS) and World Health Organization (WHO)-defined acute myeloid leukemia (AML) treated with azacitidine (AZA). There are few data available to indicate whether AZA has improved clinical activity vs conventional care in AML patients with adverse cytogenetics. However, in a subanalysis of MDS-AZA-001 (MDS and AML [20–30% bone marrow blasts]) patients with –7/–7q abnormalities had better OS with AZA than low-dose cytarabine (21.4 vs 3.5 months, respectively) supporting significant activity of AZA in patients with adverse cytogenetics.4 Methods In this retrospective study of the Austrian AZA Registry (N=346), we compared patients with WHO-AML and intermediate- (n=228) vs high-risk (n=74) cytogenetics according to Medical Research Cou...
... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wol... more ... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wolfgang Loibl 6, Ulrike Pröbstl 7 ... Transdisciplinary research uses an interdisciplinary approach and cooperation with part-ners from outside the scientific community to tackle problems ...
RÉSUMÉ Que savons-nous de la productivité naturelle des forêts alluviales des grands fleuves avan... more RÉSUMÉ Que savons-nous de la productivité naturelle des forêts alluviales des grands fleuves avant les travaux de régulation à la fin du 19eme siècle ? Quelle était leur importance en termes de ressources et de source d'énergie ? Ces modèles historiques (pré-aménagements) peuvent-ils être utilisé pour définir des objectifs en termes de gestion durable des forêts alluviales actuelles ? Une équipe interdisciplinaire composée de géomorphologues fluviaux, d'écologues forestiers et d'historien environnementaux a étudié la dynamique des paysages fluviaux dans la région de Vienne (Autriche) au début du 19 ème siècle (1825). L'objectif était de reconstituer la production annuelle potentielle de bois avant les travaux de chenalisation. Nos modèles de reconstitution des forêt alluviales et les sources historiques ont montré que la production naturelle de bois dans ces plaines alluviales était supérieure à celle observée dans des forêt alluviales actuelles quasi-pristine. Cepen...
... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wol... more ... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wolfgang Loibl 6, Ulrike Pröbstl 7 ... Transdisciplinary research uses an interdisciplinary approach and cooperation with part-ners from outside the scientific community to tackle problems ...
... Vienna, Austria; 3 Institute of Forest Growth and Yield, University of Agriculture, Vienna, A... more ... Vienna, Austria; 3 Institute of Forest Growth and Yield, University of Agriculture, Vienna, Austria (∗ author for correspondence, e-mail: Robert.Jandl@fbva ... 10 7.5YR2/1 Sandy loam Slightly stony, high content in organic mat-ter, poorly expressed mottles, weak suban-gular blocks ...
Background Few data exist reporting the incidence of World Health Organization (WHO)-defined acut... more Background Few data exist reporting the incidence of World Health Organization (WHO)-defined acute myeloid leukemia (AML) subgroups in adults in Europe,1 but the incidence of AML with myelodysplastic-related features (MRF) may be higher than initially reported.2–4 Whether the presence of multilineage dysplasia has an independent prognostic impact in AML is still controversial.5,6 However, AML patients with preceding myelodysplastic syndrome (MDS)/myeloproliferative neoplasm and/or MDS-related cytogenetics (Medical Research Council [MRC]) have been shown to have poorer survival than AML-not otherwise specified (NOS).7 Previous studies of AML patients treated with azacitidine (AZA) included AML-MRF patients, but did not report on outcomes separately.3,4, 8–12 Methods Due to the lack of data assessing the prognostic impact of AML-MRF in elderly AML patients treated with AZA, we analyzed patients with AML-MRF from the Austrian AZA Registry, which was initiated to gain a comprehensive vi...
Background The prognosis of patients with relapsed/refractory acute myeloid leukemia (AML) follow... more Background The prognosis of patients with relapsed/refractory acute myeloid leukemia (AML) following intensive chemotherapy (IC) is poor; furthermore, treatment options for these patients are limited. Few studies have assessed outcomes of azacitidine (AZA) in a relapsed/refractory setting.1–3 Response rates and survival in these studies have been variable. Methods The Austrian AZA Registry was initiated to gain a comprehensive view of the use, safety and efficacy of AZA in a broad range of ‘real-life’ AML patients. The sole inclusion criteria were the diagnosis of AML according to World Health Organization (WHO) criteria and treatment with ≥1 dose of AZA. Here, we assess clinical outcomes in patients with newly diagnosed AML (AZA 1st line) vs patients with relapsed/refractory AML following IC and/or low-dose chemotherapy/other disease-modifying therapy (AZA ≥2nd line). Results Baseline characteristics were generally comparable between patients treated with AZA 1st line (n=170) and A...
Background Approximately 10% of cases of acute myeloid leukemia (AML) arise following exposure to... more Background Approximately 10% of cases of acute myeloid leukemia (AML) arise following exposure to chemotherapy (treatment-related AML [tAML]). Compared to de novo AML patients, tAML patients have a poor prognosis, not least due to a higher proportion having adverse cytogenetics. Treatment options for tAML patients are limited and outcomes remain dismal. Median overall survival (OS) of 6.9 mo as of initial presentation, with 25% deaths within one month of diagnosis, was reported for a large cohort of tAML patients, with individualized treatments ranging from supportive care, to intensive chemotherapy (IC) and bone marrow (BM) transplantation.1 Few studies have assessed azacitidine (AZA) in patients with tAML, and those that have, did not report separate outcomes for this subgroup.2–4 Methods Here, we compare a subgroup of tAML patients (n=27) with patients with other World Health Organization (WHO)-AML subgroups (n=319) from the Austrian AZA Registry. The aim of the registry was to g...
Crown-condition assessment, hypothesized to estimate needle losses following damage from several ... more Crown-condition assessment, hypothesized to estimate needle losses following damage from several sources, one of which might be air pollution, suffers from the subjective notion of a standard "healthy" tree. On the other hand, the foliage biomass - sapwood area ratios are reported to depend on a number of factors, e.g., site quality, stand density, crown class, and tree ring width conductivity. The authors hypothesize that early sapwood area might help to even better estimate needle biomass of Norway spruce (Picea abies (L.) Karst.) and to help standardize crown-condition assessment. Thirty-six Norway spruce trees at two Austrian sites, from three age-classes, three crown classes, and two crown-condition classes were felled. Needle mass, cross-sectional area, sapwood area, and early sapwood area (i.e., sapwood area excluding latewood) were measured. The results of this study indicate that indeed early sapwood area is a good estimator of foliage, independent of site, age, crown class, and crown condition. The ratio between early sapwood area and cross-sectional area could be a good estimator for crown condition and thus help to standardize crown-condition assessments by different surveyors.
ABSTRACT Original inClimate Change and Impacts on Water SupplyAppendix IForests, Water Protection... more ABSTRACT Original inClimate Change and Impacts on Water SupplyAppendix IForests, Water Protection and Climate ChangeReports of the BOKU -- Forest Group to WP 5
Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone mar... more Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Azacitidine Registry (clinicaltrials.gov identifier NCT01595295). We herein update this report with a population almost twice as large (n = 302). This cohort included 172 patients with >30 % BM blasts; 93 % would have been excluded from the pivotal AZA-001 trial (which led to European Medicines Agency (EMA) approval of azacitidine for high-risk myelodysplastic syndromes (MDS) and AML with 20-30 % BM blasts). Despite this much more unfavorable profile, results are encouraging: overall response rate was 48 % in the total cohort and 72 % in patients evaluable according to MDS-IWG-2006 response criteria, respectively. Median OS was 9.6 (95 % CI 8.53-10.7) months. A clinically relevant OS ben...
Background Several studies, including retrospective analyses of patient registries1,2 and a suban... more Background Several studies, including retrospective analyses of patient registries1,2 and a subanalysis of the phase III MDS-AZA-001 trial3 suggest that poor-risk cytogenetics negatively impact overall survival (OS) in patients with myelodysplastic syndrome (MDS) and World Health Organization (WHO)-defined acute myeloid leukemia (AML) treated with azacitidine (AZA). There are few data available to indicate whether AZA has improved clinical activity vs conventional care in AML patients with adverse cytogenetics. However, in a subanalysis of MDS-AZA-001 (MDS and AML [20–30% bone marrow blasts]) patients with –7/–7q abnormalities had better OS with AZA than low-dose cytarabine (21.4 vs 3.5 months, respectively) supporting significant activity of AZA in patients with adverse cytogenetics.4 Methods In this retrospective study of the Austrian AZA Registry (N=346), we compared patients with WHO-AML and intermediate- (n=228) vs high-risk (n=74) cytogenetics according to Medical Research Cou...
... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wol... more ... Ika Darnhofer 1, Ingeborg Auer 2, Otto Eckmüllner 3,Veronika Gaube 4, Anna Kirchengast 5, Wolfgang Loibl 6, Ulrike Pröbstl 7 ... Transdisciplinary research uses an interdisciplinary approach and cooperation with part-ners from outside the scientific community to tackle problems ...
RÉSUMÉ Que savons-nous de la productivité naturelle des forêts alluviales des grands fleuves avan... more RÉSUMÉ Que savons-nous de la productivité naturelle des forêts alluviales des grands fleuves avant les travaux de régulation à la fin du 19eme siècle ? Quelle était leur importance en termes de ressources et de source d'énergie ? Ces modèles historiques (pré-aménagements) peuvent-ils être utilisé pour définir des objectifs en termes de gestion durable des forêts alluviales actuelles ? Une équipe interdisciplinaire composée de géomorphologues fluviaux, d'écologues forestiers et d'historien environnementaux a étudié la dynamique des paysages fluviaux dans la région de Vienne (Autriche) au début du 19 ème siècle (1825). L'objectif était de reconstituer la production annuelle potentielle de bois avant les travaux de chenalisation. Nos modèles de reconstitution des forêt alluviales et les sources historiques ont montré que la production naturelle de bois dans ces plaines alluviales était supérieure à celle observée dans des forêt alluviales actuelles quasi-pristine. Cepen...
Uploads
Papers by Otto Eckmüllner